Zobrazeno 1 - 10
of 197
pro vyhledávání: ''
Autor:
Russ Wada, Ophelia Yin, Malaz Abutarif, Frank LaCreta, Seiko Endo, Kazutaka Yoshihara, Yuan Xiong, Tushar Garimella
Publikováno v:
Clinical Pharmacology and Therapeutics
Trastuzumab deruxtecan (DS-8201) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate with a novel enzyme-cleavable linker, a topoisomerase I inhibitor payload, and a drug-to-antibody ratio of ≈ 8. We have characte
Autor:
Jacqueline G Gerhart, Dan L. Stewart, Namasivayam Ambalavanan, Gregory M Sokol, Daniel Gonzalez, Matthew M. Laughon, Chi D. Hornik, Andrea N. Edginton, Sara Salerno, Mary Mills, Karen Martz
Publikováno v:
Clinical pharmacology and therapeutics
Physiologically-based pharmacokinetic (PBPK) modeling can potentially predict pediatric drug-drug interactions (DDIs) when clinical DDI data are limited. In infants for whom treatment of pulmonary hypertension and prevention or treatment of invasive
Autor:
Marietta Kollars, Jolanta M. Siller-Matula, Martin F. Wolkersdorfer, Alexandra Kaider, Paul A. Kyrle, Ludwig Traby, Sabine Eichinger, Michael Wolzt
Publikováno v:
Clinical Pharmacology and Therapeutics
Dual antiplatelet therapy (DAPT) is standard in acute coronary syndrome but confers a bleeding risk. To compare effects of clopidogrel single antiplatelet therapy (SAPT) with clopidogrel-based DAPT on hemostatic system activation we conducted a rando
Autor:
Guilherme Suarez-Kurtz
Publikováno v:
Clinical pharmacology and therapeutics. 110(3)
Plasmodium vivax (P. vivax) is the most widespread human malaria parasite, with 2.5 billion people at risk of infection worldwide. P. vivax forms liver hypnozoites, which trigger further symptomatic episodes (relapses) weeks or months after the initi
Autor:
Poulami Barman, Barbara Goodnature, Huanyao Gao, Lois E. Shepherd, Erin E. Carlson, Richard M. Weinshilboum, Matthew P. Goetz, James N. Ingle, Junmei Cairns, Krishna R. Kalari, Liewei Wang, Matthew J. Ellis, Paul E. Goss
Publikováno v:
Clinical Pharmacology and Therapeutics
Aromatase inhibitors (AIs) are the treatment of choice for hormone receptor-positive early breast cancer in postmenopausal women. None of the third-generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic facto
Autor:
Norman Stockbridge, Michael Pacanowski, Jielin Sun, T. Beasley, Nita A. Limdi, Jeffry Florian
Publikováno v:
Clin Pharmacol Ther
Chronic kidney disease is a common comorbidity among patients taking direct-acting oral anticoagulants (DOACs). Herein, we evaluate the influence of kidney function on stroke or systemic embolism (SEE), hemorrhage, and composite end points (stroke/SE
Publikováno v:
Clin Pharmacol Ther
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease, is increasing in prevalence. NASH-related alterations in hepatic protein expression (e.g., transporters) and in overall physiology may affect drug exposure
Autor:
Adriana Weinberg, Tsungai Mhembere, Grace Montepiedra, Ramesh Bhosale, Kamunkhwala Gausi, Tichaona Vhembo, Lubbe Wiesner, Lisa Aaron, Amita Gupta, Timothy R. Sterling, David W. Haas, Carole L. Wallis, Jennifer Norman, Nahida Chakhtoura, Avy Violari, Katie McCarthy, Enid Kabugho, Lynda Stranix-Chibanda, Vanessa Rouzier, Mercy Mutambanengwe, Katherine Shin, Bonnie Zimmer, Sarah Bradford, Fuanglada Tongprasert, Diane Costello, Renee Browning, Gerhard Theron, Tsungai Chipato, Linda Aurpibul, Blandina T. Mmbaga, Patrick Jean-Philippe, Vongai Chanaiwa, Neetal Nevrekhar, Anneke C. Hesseling, Paolo Denti, Mandisa Nyati, Gaerolwe Masheto, Carolyne Onyango-Makumbi
Publikováno v:
Clinical Pharmacology and Therapeutics
The World Health Organization guidelines recommend that individuals living with HIV receive ≥ 6 months of isoniazid preventive therapy, including pregnant women. Yet, plasma isoniazid exposure during pregnancy, in the antiretroviral therapy era, ha
Autor:
Ahmed Salem, Walid M. Awni, Rod A. Humerickhouse, Dale Miles, Sathej Gopalakrishnan, Kevin J. Freise, William G. Wierda, Brenda Chyla, Sven Mensing, Rajeev M. Menon
Publikováno v:
Clinical pharmacology and therapeutics. 109(2)
Minimal residual disease (MRD) is an important emerging clinical end point in chronic lymphocytic leukemia (CLL). The objective of this research was to develop an integrated mechanistic model to evaluate the impact of venetoclax-rituximab combination
Publikováno v:
Clinical Pharmacology and Therapeutics
The antibody-drug conjugate (ADC) brentuximab vedotin consists of the CD30-directed antibody attached to the microtubule-disrupting agent monomethyl auristatin E (MMAE). In pharmacokinetic models, including data from six studies (380 patients with cl